Summary:

Antibody therapeutics are increasingly engineered with Fc modifications to fine-tune efficacy, extend half-life, or reduce effector function, but these changes come with risk. The complexity of Fc biology, combined with the interplay between Fab and Fc domains, means that intended outcomes don't always align with reality.

In this scientific briefing, Dr. Shashi Jatiani presents real-world examples where Fc engineering led to unexpected functional changes, despite rational design, and highlights how SeromYx’s high-throughput, antigen-specific Fc effector function platform can be used to detect, predict, and optimize antibody function across development stages.

Key takeaways include:

• Why Fc function is more than receptor binding, it’s tripartite and context-dependent
  
• Data showing how half-life extension mutations can reduce ADCC, ADNP, and NK cell activation
  
• Novel functional profiling of anti-CD20 mAbs, revealing effector functions beyond ADCC and CDC
  
• How SeromYx’s platform enables robust, scalable Fc characterization to support IND and BLA filings